Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447829 | 0.80 | ALDH1A1 (0.33) | TDP1 | |
| SCHEMBL2866749 | 0.74 | CYP4F2 (0.36) | — | |
| SCHEMBL12581238 | 0.71 | ACLY (0.35) | TDP1 | |
| SCHEMBL21340475 | 0.70 | TSHR (0.38) | TDP1 | |
| SCHEMBL2876463 | 0.69 | POLB (0.36) | — | |
| SCHEMBL4612722 | 0.68 | — | — | |
| SCHEMBL354406 | 0.68 | DGAT1 (0.33) | TDP1 | |
| SCHEMBL11051455 | 0.68 | — | — | |
| SCHEMBL24633725 | 0.67 | GGT1 (0.37) | TDP1 | |
| SCHEMBL25315695 | 0.67 | GGT1 (0.37) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120965-B1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8415497-B2 | N-halogenated amino compounds and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | DCTD, DDC, DAO | TDP1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.